home / stock / abus / abus quote
Last: | $3.78 |
---|---|
Change Percent: | 2.06% |
Open: | $3.8 |
Close: | $3.78 |
High: | $3.8299 |
Low: | $3.67 |
Volume: | 1,255,643 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.78 | $3.8 | $3.78 | $3.8299 | $3.67 | 1,255,643 | 07-17-2024 |
$3.88 | $3.79 | $3.88 | $3.89 | $3.73 | 1,405,430 | 07-16-2024 |
$3.75 | $3.54 | $3.75 | $3.79 | $3.54 | 1,342,628 | 07-15-2024 |
$3.59 | $3.55 | $3.59 | $3.65 | $3.51 | 849,268 | 07-12-2024 |
$3.51 | $3.415 | $3.51 | $3.52 | $3.3993 | 1,246,153 | 07-11-2024 |
$3.41 | $3.4 | $3.41 | $3.43 | $3.34 | 1,048,923 | 07-10-2024 |
$3.4 | $3.24 | $3.4 | $3.41 | $3.24 | 1,013,124 | 07-09-2024 |
$3.26 | $3.14 | $3.26 | $3.32 | $3.135 | 1,210,639 | 07-08-2024 |
$3.12 | $3.15 | $3.12 | $3.15 | $3.05 | 663,041 | 07-05-2024 |
$3.16 | $3.15 | $3.16 | $3.22 | $3.13 | 661,835 | 07-04-2024 |
$3.16 | $3.15 | $3.16 | $3.22 | $3.13 | 661,835 | 07-03-2024 |
$3.13 | $3.12 | $3.13 | $3.14 | $3.09 | 856,611 | 07-02-2024 |
$3.12 | $3.07 | $3.12 | $3.15 | $3.05 | 722,406 | 07-01-2024 |
$3.09 | $3.12 | $3.09 | $3.2 | $2.99 | 4,407,796 | 06-28-2024 |
$3.1 | $3.03 | $3.1 | $3.14 | $3.03 | 644,004 | 06-27-2024 |
$3.01 | $3.02 | $3.01 | $3.03 | $2.945 | 645,297 | 06-26-2024 |
$3.05 | $3.06 | $3.05 | $3.08 | $2.99 | 598,659 | 06-25-2024 |
$3.07 | $3.09 | $3.07 | $3.115 | $3.03 | 734,374 | 06-24-2024 |
$3.05 | $3 | $3.05 | $3.07 | $2.96 | 2,110,757 | 06-21-2024 |
$2.95 | $3 | $2.95 | $3.01 | $2.915 | 1,289,773 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment ...